Satvik Dasariraju

age1 thesis

About Portfolio Team Library Early backer of breakthrough, founder-led longevity companies All age1 The Longevity Fund Precision therapeutics for genetic forms of neurodegeneration EXITED: IPO First-in-class foundational checkpoint immunotherapies NASDAQ: ALXO Discovering new medicines with ultra-throughput biochemistry and machine learning Next-generation interventions to cure neurodegeneration and delay brain aging Targeting pathogenic cells to treat aging and chronic diseases Turning stem cells into human eggs to reimagine family planning EXITED: IPO Regenerative and gene therapies to resto

Sector and stage focus

• Series A: Therapeutics, BioTech
• Pre-seed: Therapeutics, BioTech
• Seed: Therapeutics, BioTech
• general: Boston / New England

Is Satvik Dasariraju a fit for your round?

Upload your pitch deck and see whether Satvik Dasariraju appears in your top 20 matches.